Dr Reddy's Laboratories (DRL) has commenced their phase 2 and phase 3 clinical trials for Sputnik V vaccine in India in association with the Russian Direct Investment Fund (RDIF). The partnership is to conduct clinical trials of Sputnik V vaccine and distribute the first 100 million doses in India.
GV Prasad, CO- Chairman and MD of DRL discussed the developments in an interview to CNBC-TV18.
“We have commenced phase-II trials for Sputnik-V vaccine in India a few weeks ago,” he said in an interview with CNBC-TV18.
“We expect it (phase 2) to be completed in early January and phase 3 by March,” he said.
When asked about the logistic requirement, he replied, “The logistics, the cold chain, everything is key in this product. The vaccine has stability at -18 degrees centigrade which is still a big challenge, but India has some experience for -20 degrees for a measles vaccine and hopefully we can leverage on that experience.”
In terms of distribution, he said, “We are setting up 13 nodes of distribution throughout the country and are working on the cold chain, ensuring that we use tracking mechanisms to ensure the integrity of the temperatures and we are also looking at other ways to digitally ensure that the first shot and the booster shot are taken by everybody.”
For full interview, watch the video
(Edited by : Abhishek Jha)
First Published: IST